Published in Cell Stem Cell on June 05, 2009
Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem (2009) 1.35
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Immune therapeutic targeting of glioma cancer stem cells. Target Oncol (2010) 0.95
Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev (2013) 0.84
Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells. PLoS One (2015) 0.78
CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population. Stem Cells Transl Med (2015) 0.76
Success of tumorsphere isolation from WHO grade IV gliomas does not correlate with the weight of fresh tumor specimens: an immunohistochemical characterization of tumorsphere differentiation. Cancer Cell Int (2016) 0.75
Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation. Curr Stem Cell Rep (2016) 0.75
PNIPAAm-co-Jeffamine(®) (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells. Biomaterials (2017) 0.75
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res (2009) 3.58
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res (2008) 2.22
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16
Primary central nervous system lymphoma: time to ask the question. J Clin Oncol (2002) 1.92
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest (2004) 1.85
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer (2002) 1.62
Predicting in vitro drug sensitivity using Random Forests. Bioinformatics (2010) 1.59
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol (2009) 1.51
Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer (2005) 1.50
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol (2009) 1.41
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2004) 1.33
Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis (2008) 1.33
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev (2003) 1.28
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol (2009) 1.23
Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev (2006) 1.23
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia (2008) 1.21
Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol (2011) 1.20
Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev (2007) 1.17
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol (2003) 1.15
Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol (2008) 1.13
Prediction of Associations between microRNAs and Gene Expression in Glioma Biology. PLoS One (2011) 1.10
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.09
Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res (2004) 1.09
Many tumors in one: a daunting therapeutic prospect. Cancer Cell (2011) 1.09
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol (2011) 1.09
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol (2010) 1.08
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer (2014) 1.07
Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest (2008) 1.06
Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes. Cancer Res (2009) 1.04
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst (2007) 1.03
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS One (2012) 1.02
Bevacizumab for malignant gliomas. Arch Neurol (2010) 1.02
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol (2011) 0.99
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol (2004) 0.99
Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol (2012) 0.99
A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol (2012) 0.97
Cancer in first-degree relatives and risk of glioma in adults. Cancer Epidemiol Biomarkers Prev (2003) 0.97
Sociodemographic indicators and risk of brain tumours. Int J Epidemiol (2003) 0.97
Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. Cancer Res (2003) 0.96
Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev (2009) 0.96
A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res (2009) 0.96
G-cimp status prediction of glioblastoma samples using mRNA expression data. PLoS One (2012) 0.96
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol (2009) 0.94
Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev (2010) 0.94
Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res (2004) 0.94
Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors. Neuro Oncol (2006) 0.93
Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys J (2011) 0.93
Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood (2005) 0.91
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia (2002) 0.91
The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathol Commun (2013) 0.90
Occupation and risk of meningioma and acoustic neuroma in the United States. Am J Ind Med (2004) 0.90
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer (2010) 0.90
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol (2008) 0.88
Gene pathways and subnetworks distinguish between major glioma subtypes and elucidate potential underlying biology. J Biomed Inform (2010) 0.88
Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol (2014) 0.88
Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol (2008) 0.87
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol (2011) 0.87
Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res (2012) 0.87
FastMEDUSA: a parallelized tool to infer gene regulatory networks. Bioinformatics (2010) 0.85
Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Malignant gliomas: new translational therapies. Mt Sinai J Med (2010) 0.85
Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect (2005) 0.85
Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS One (2013) 0.85
SnapShot: glioblastoma multiforme. Cancer Cell (2012) 0.85
Handedness and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev (2003) 0.84
Occupational exposure to magnetic fields and the risk of brain tumors. Neuro Oncol (2009) 0.84
GliomaPredict: a clinically useful tool for assigning glioma patients to specific molecular subtypes. BMC Med Inform Decis Mak (2010) 0.83
Refining endpoints in brain tumor clinical trials. J Neurooncol (2012) 0.83
Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults. Am J Epidemiol (2006) 0.82
Evaluation of (76)Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma. J Nucl Med (2005) 0.82
Meningioma and schwannoma risk in adults in relation to family history of cancer. Neuro Oncol (2004) 0.81
Toward a glioblastoma vaccine: promise and potential pitfalls. J Clin Oncol (2004) 0.80
Antiangiogenic therapy for primary and metastatic brain tumors. Hematol Oncol Clin North Am (2004) 0.80
Polyomavirus and medulloblastoma: a smoking gun or guilt by association? J Natl Cancer Inst (2002) 0.80
Self-reported electrical appliance use and risk of adult brain tumors. Am J Epidemiol (2005) 0.80